Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Current Assets (2022 - 2025)

BioXcel Therapeutics has reported Current Assets over the past 4 years, most recently at $44.7 million for Q4 2025.

  • Quarterly results put Current Assets at $44.7 million for Q4 2025, up 19.5% from a year ago — trailing twelve months through Dec 2025 was $44.7 million (up 19.5% YoY), and the annual figure for FY2025 was $44.7 million, up 19.5%.
  • Current Assets for Q4 2025 was $44.7 million at BioXcel Therapeutics, up from $44.4 million in the prior quarter.
  • Over the last five years, Current Assets for BTAI hit a ceiling of $244.9 million in Q2 2022 and a floor of $25.2 million in Q2 2025.
  • Median Current Assets over the past 4 years was $76.5 million (2023), compared with a mean of $110.4 million.
  • Biggest five-year swings in Current Assets: plummeted 64.44% in 2023 and later rose 19.5% in 2025.
  • BioXcel Therapeutics' Current Assets stood at $202.9 million in 2022, then plummeted by 64.44% to $72.1 million in 2023, then tumbled by 48.17% to $37.4 million in 2024, then rose by 19.5% to $44.7 million in 2025.
  • The last three reported values for Current Assets were $44.7 million (Q4 2025), $44.4 million (Q3 2025), and $25.2 million (Q2 2025) per Business Quant data.